{
    "clinical_study": {
        "@rank": "8189", 
        "arm_group": [
            {
                "arm_group_label": "A = PF-06438179", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "B = Infliximab-EU", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "C = Infliximab-US", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, healthy volunteers will receive a single intravenous dose of either\n      PF-06438179 or infliximab (United States) or infliximab (European Union).  During the course\n      of the study, the pharmacokinetics will be assessed by sampling the levels of drug in the\n      blood, and by comparing these levels among the different administration arms of PF-06438179\n      and the licensed infliximab products.  Safety, tolerability, and immunologic response will\n      also be evaluated throughout."
        }, 
        "brief_title": "A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female subjects of non-childbearing potential and healthy male subjects\n             (healthy is defined as no clinically relevant abnormalities identified by a detailed\n             medical history, full physical examination, including blood pressure and pulse rate\n             measurement, 12-lead ECG and clinical laboratory tests).\n\n          -  Body Mass Index (BMI) of 17.5 to 32.0 kg/m2; and a total body weight >50kg (110 lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant infectious, hematological, renal,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,\n             neurologic, autoimmune, or allergic disease (including drug allergies, but excluding\n             untreated, asymptomatic, seasonal allergies at time of dosing).\n\n          -  Previous exposure to a monoclonal antibody, or current use of other biologics.\n\n          -  History of hypersensitivity reaction to inactive components of the study drugs or any\n             murine proteins or anaphylactic reactions to therapeutic drugs.\n\n          -  History of tuberculosis (TB) or a positive latent TB test at Screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "146", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844804", 
            "org_study_id": "B5371001", 
            "secondary_id": "REFLECTIONS B537-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A = PF-06438179", 
                "description": "Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1", 
                "intervention_name": "PF-06438179", 
                "intervention_type": "Biological", 
                "other_name": "Infliximab-Pfizer"
            }, 
            {
                "arm_group_label": "B = Infliximab-EU", 
                "description": "Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1", 
                "intervention_name": "Remicade", 
                "intervention_type": "Biological", 
                "other_name": "Infliximab (European Union)"
            }, 
            {
                "arm_group_label": "C = Infliximab-US", 
                "description": "Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1", 
                "intervention_name": "Remicade", 
                "intervention_type": "Biological", 
                "other_name": "Infliximab (United States)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Bioequivalence", 
            "Biosimilarity", 
            "Similarity", 
            "PK", 
            "Phase 1", 
            "Infliximab", 
            "Healthy Volunteers", 
            "Single-dose", 
            "Immunology"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5371001&StudyName=A%20Pharmacokinetics%20Study%20Comparing%20PF-06438179%20and%20Infliximab%20in%20Healthy%20Volunteers%20%28REFLECTIONS%20B537-01%29"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66212"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study of PF-06438179 and Infliximab Sourced From US and EU Administered to Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Serum Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUCt)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero Extrapolated to Infinite Time (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844804"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }, 
            {
                "measure": "Terminal Disposition Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }, 
            {
                "measure": "Volume of Distribution at Steady State (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 57"
            }, 
            {
                "measure": "Incidence of anti-infliximab antibodies (ADA), including neutralizing antibodies (Nab)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 - LSLV or Day 85 whichever occurs later"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}